IL270787B2 - Melanoma detection methods - Google Patents
Melanoma detection methodsInfo
- Publication number
- IL270787B2 IL270787B2 IL270787A IL27078719A IL270787B2 IL 270787 B2 IL270787 B2 IL 270787B2 IL 270787 A IL270787 A IL 270787A IL 27078719 A IL27078719 A IL 27078719A IL 270787 B2 IL270787 B2 IL 270787B2
- Authority
- IL
- Israel
- Prior art keywords
- expression level
- cflar
- hla
- subject
- melanoma
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511058P | 2017-05-25 | 2017-05-25 | |
| PCT/US2018/033658 WO2018217627A1 (en) | 2017-05-25 | 2018-05-21 | Methods for melanoma detection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL270787A IL270787A (en) | 2020-01-30 |
| IL270787B1 IL270787B1 (en) | 2023-04-01 |
| IL270787B2 true IL270787B2 (en) | 2023-08-01 |
Family
ID=62620988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270787A IL270787B2 (en) | 2017-05-25 | 2019-11-20 | Melanoma detection methods |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180340934A1 (enExample) |
| EP (1) | EP3631017B1 (enExample) |
| JP (1) | JP7227964B2 (enExample) |
| KR (1) | KR102763004B1 (enExample) |
| CN (1) | CN111315897B (enExample) |
| AU (1) | AU2018273844B2 (enExample) |
| BR (1) | BR112019024481A2 (enExample) |
| CA (1) | CA3064732A1 (enExample) |
| DK (1) | DK3631017T3 (enExample) |
| ES (1) | ES2920288T3 (enExample) |
| IL (1) | IL270787B2 (enExample) |
| MX (1) | MX2019014026A (enExample) |
| PL (1) | PL3631017T3 (enExample) |
| WO (1) | WO2018217627A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019024481A2 (pt) | 2017-05-25 | 2020-07-14 | Liquid Biopsy Research LLC | métodos para detecção de melanoma |
| US20210108259A1 (en) | 2019-10-10 | 2021-04-15 | Liquid Biopsy Research LLC | Compositions, methods and kits for biological sample and rna stabilization |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2614946A1 (en) * | 2005-01-07 | 2006-07-13 | The Johns Hopkins University | Biomarkers for melanoma |
| US7615349B2 (en) * | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| EP2080140B1 (en) * | 2006-11-03 | 2013-04-24 | Baylor Research Institute | Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis |
| EP2092075A2 (en) * | 2006-11-06 | 2009-08-26 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring and treatment of melanoma |
| US20110070582A1 (en) * | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
| US20110091384A1 (en) * | 2009-10-13 | 2011-04-21 | The Johns Hopkins University | Biomarker for identification of melanoma tumor cells |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| CN104470920A (zh) * | 2012-07-03 | 2015-03-25 | 通益制药有限公司 | 固态形式的维罗菲尼胆碱盐 |
| AU2015317893B2 (en) * | 2014-09-15 | 2021-05-20 | Clifton Life Sciences LLC | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm |
| BR112019024481A2 (pt) | 2017-05-25 | 2020-07-14 | Liquid Biopsy Research LLC | métodos para detecção de melanoma |
-
2018
- 2018-05-21 BR BR112019024481-6A patent/BR112019024481A2/pt unknown
- 2018-05-21 CN CN201880049298.1A patent/CN111315897B/zh active Active
- 2018-05-21 JP JP2020516379A patent/JP7227964B2/ja active Active
- 2018-05-21 MX MX2019014026A patent/MX2019014026A/es unknown
- 2018-05-21 EP EP18731615.3A patent/EP3631017B1/en active Active
- 2018-05-21 KR KR1020197038285A patent/KR102763004B1/ko active Active
- 2018-05-21 CA CA3064732A patent/CA3064732A1/en active Pending
- 2018-05-21 ES ES18731615T patent/ES2920288T3/es active Active
- 2018-05-21 WO PCT/US2018/033658 patent/WO2018217627A1/en not_active Ceased
- 2018-05-21 US US15/984,935 patent/US20180340934A1/en not_active Abandoned
- 2018-05-21 PL PL18731615.3T patent/PL3631017T3/pl unknown
- 2018-05-21 AU AU2018273844A patent/AU2018273844B2/en active Active
- 2018-05-21 DK DK18731615.3T patent/DK3631017T3/da active
-
2019
- 2019-11-20 IL IL270787A patent/IL270787B2/en unknown
-
2021
- 2021-09-30 US US17/490,433 patent/US12399179B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3631017T3 (da) | 2022-06-20 |
| JP7227964B2 (ja) | 2023-02-22 |
| EP3631017A1 (en) | 2020-04-08 |
| MX2019014026A (es) | 2020-08-03 |
| PL3631017T3 (pl) | 2022-09-26 |
| WO2018217627A1 (en) | 2018-11-29 |
| AU2018273844A1 (en) | 2019-12-19 |
| JP2020524524A (ja) | 2020-08-20 |
| US20180340934A1 (en) | 2018-11-29 |
| BR112019024481A2 (pt) | 2020-07-14 |
| ES2920288T3 (es) | 2022-08-02 |
| IL270787B1 (en) | 2023-04-01 |
| KR102763004B1 (ko) | 2025-02-04 |
| EP3631017B1 (en) | 2022-03-23 |
| CN111315897B (zh) | 2024-10-22 |
| KR20200030034A (ko) | 2020-03-19 |
| US12399179B2 (en) | 2025-08-26 |
| IL270787A (en) | 2020-01-30 |
| CN111315897A (zh) | 2020-06-19 |
| AU2018273844B2 (en) | 2024-11-14 |
| US20230022236A1 (en) | 2023-01-26 |
| CA3064732A1 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015334842B2 (en) | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities | |
| AU2015334841B2 (en) | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities | |
| CN110382521B (zh) | 从氧化应激区分肿瘤抑制性foxo活性的方法 | |
| CN107077536B (zh) | 使用靶基因表达的数学建模评价TGF-β细胞信号传导途径的活性 | |
| KR102023584B1 (ko) | 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법 | |
| RU2721916C2 (ru) | Способы прогнозирования рака предстательной железы | |
| AU2015360694B2 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
| KR101421326B1 (ko) | 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트 | |
| CN101687050A (zh) | 用于鉴别原发起源不明的癌的起源的方法和材料 | |
| AU2018210695A1 (en) | Molecular subtyping, prognosis, and treatment of bladder cancer | |
| US20090305284A1 (en) | Methods for Identifying Risk of Breast Cancer and Treatments Thereof | |
| KR20140140069A (ko) | 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법 | |
| CN101573453A (zh) | 使用生物学途径基因表达分析来预测淋巴结阴性原发性乳腺癌的远处转移的方法 | |
| US12366575B2 (en) | Chemical compositions and methods of use | |
| US12399179B2 (en) | Chemical compositions and methods of use | |
| KR20060045950A (ko) | 혈액학적 악성종양에 대한 예후 | |
| CN101111768A (zh) | 肺癌预后 | |
| CN101827948A (zh) | 检测鳞状细胞癌和腺癌及其高级别癌前病变的新分子标记 | |
| CN101126106A (zh) | 胃癌辅助诊断的基因序列及其应用 | |
| HK1141723A (en) | Methods and materials for identifying the origin of a carcinoma of unknown primary origin | |
| HK1084696A (en) | Prognostic for hematological malignancy |